Eczema linked to higher risk of death from all causes

Atopic dermatitis is usually thought of as a skin problem — itchy, uncomfortable, sometimes miserable, but rarely framed as a matter of life and death. Researchers have increasingly asked whether the condition tracks with broader health outcomes, including the ultimate one: risk of dying, from any cause and from specific causes. Individual cohort studies have compared mortality in people with atopic dermatitis against controls, but single studies can mislead. Pooling them in a meta-analysis gives a clearer answer to whether the condition carries risks that extend well beyond the skin.

The authors systematically searched PubMed, EMBASE and the Cochrane Library from inception to April 2025 for cohort studies comparing mortality risks in people with atopic dermatitis against controls, following PRISMA guidelines. Two reviewers independently screened studies, extracted the data and assessed study quality using the Newcastle-Ottawa Scale. Hazard ratios were then pooled using random-effects models, and the team ran sensitivity analyses, subgroup analyses and assessments for publication bias. Nine cohort studies met the inclusion criteria and were combined in the final analysis.

People with atopic dermatitis had a significantly higher risk of all-cause mortality, with a pooled hazard ratio of 1.222 (95% CI 1.117-1.336). Cause-specific risks were also elevated: mortality from infectious diseases (HR 1.606), respiratory diseases (HR 1.381), gastrointestinal diseases (HR 1.658) and cancer (HR 1.129). Notably, the confidence intervals for the gastrointestinal and cancer estimates only just cleared the line of no effect, so those signals are less firm. Subgroup analyses showed a higher all-cause mortality risk in prospective studies than retrospective ones, and significantly higher risks in studies from Europe and Asia.

This pooled analysis strengthens the case that atopic dermatitis is associated with health risks beyond the skin, echoing a broader shift towards viewing it as a condition with systemic implications. Because all nine included studies were observational cohorts, the analysis cannot establish that the condition causes earlier death — people with atopic dermatitis may differ from controls in ways the original studies could not fully account for. The variation by study design and region also leaves questions open, and the authors themselves call for research in more diverse populations with a wider range of study designs.

If you have eczema, this is a reason to think of it as connected to your overall health picture rather than a purely cosmetic or skin-deep issue. The absolute meaning of a hazard ratio of 1.222 for any one person is modest, and nothing here shows that the condition itself is doing the damage — the pathways could run through infection risk, respiratory disease or shared underlying factors. The authors frame the finding as an argument for better monitoring of people with atopic dermatitis, not as a cause for alarm. It is a signal worth knowing about, not a prognosis.